Business

Theravance has announced that its LABA Royalty Sub wholly owned subsidiary "issued $450 million in aggregate principal amount of PhaRMA 9% Notes due on or before May 15, 2029. The notes are secured by a security interest in a segregated bank account established to receive 40% of royalties from global net sales of Relvar/Breo Ellipta (fluticasone furoate/vilanterol … [Read more...] about Theravance announces $450 million in financing

US pharmaceutical company OPKO Health has announced that it will acquire Israeli device company Inspiro Medical whose only product is the Inspiromatic dry powder inhaler. In June 2013, Inspiro announced positive results from a study of the device used to deliver formoterol. OPKO CEO and Chairman Phillip Frost said, "We are pleased to add this next generation … [Read more...] about OPKO Health acquires Inspiro Medical and its Inspiromatic DPI

Inhaled drug developer Prosonix has announced a global licensing agreement with Mylan for its generic versions of GSK's Flixotide and Flovent fluticasone propionate MDIs for the treatment of asthma. The deal covers two Prosonix MDIs, PSX1001 and PSX1050, with the same particle engineered formulation of fluticasone; PSX1050 differs from PSX1001 only in having a dose … [Read more...] about Prosonix licenses two MDIs to Mylan

According to Hovione, the United States Patent and Trademark Office (USPTO) has granted the company a patent for its XCAPs capsule-based dry powder inhaler. The European Patent Office granted the company a patent for the inhaler in September, 2013. Hovione VP Peter Villax, who is a co-inventor of the DPI, commented, “We give our customers an edge in speed of … [Read more...] about Hovione gets US patent for XCaps inhaler

Swedish pharmaceutical company Meda has confirmed that Mylan approached the company with a takeover offer and that Meda rejected the offer. According to Meda, "All continued discussions between Meda and Mylan have been terminated without further actions." In June 2013, Meda denied that it was in talks to be acquired by Sun Pharmaceuticals. Meda's products … [Read more...] about Meda rejects Mylan offer

Swedish CDMO Recipharm, which has a dedicated DPI manufacturing facility in the UK, has begun trading on the Stockholm stock exchange, according to NASDAQ OMX. Recipharm had announced the IPO in March 2014. Recipharm CEO Thomas Eldered said, “Today marks the beginning of a new phase in Recipharm’s life. We welcome all our new shareholders who have demonstrated their … [Read more...] about Recipharm begins trading on Stockholm stock exchange

Skyepharma revenues were up 25% in 2013, the company said, in large part due to increased sales of its Flutiform fluticasone/formoterol MDI. The company also announced that it will seek to raise £112 million through a firm placing and a placing and open offer of over 58,680,000 ordinary shares at a price of 191 pence. Skyepharma CEO Peter Grant commented, "2013 … [Read more...] about Skyepharma revenues up on increased Flutiform sales, looks to raise £112 million

NanoBio has announced that Merck has acquired exclusive rights to NanoBio's NanoStat nanoemulsion adjuvant for an intranasal respiratory syncytial virus (RSV) vaccine. Merck also acquired non-exclusive rights to the adjuvant for use in an intranasal flu vaccine. The amount of the deal, which includes an upfront payment, milestone payments, and royalties on any sales … [Read more...] about Merck licenses adjuvant technology from NanoBio for intranasal RSV vaccine